| Literature DB >> 31041185 |
Asmatanzeem Bepari1, Shaik Kalimulla Niazi2, Ishrat Rahman3, Asmabi Makandar Dervesh4.
Abstract
In India, the under-reporting of adverse drug reactions (ADRs) by health professionals is recognized as one of the leading reasons of poor ADR signal detection. The knowledge of ADRs and positive attitude of health-care professionals toward ADRs reporting is vital for decreasing the irrational use of an inappropriate pharmacy. The present study was directed to assess the knowledge, attitude, and practice (KAP) of pharmacovigilance (PV) among the physicians, nurses, and pharmacists of a teaching tertiary care hospital of India. A structured questionnaire was designed using previous studies and standardized. Questions were categorized into three groups: Group 1 tested the knowledge (K1-K8), Group 2 tested attitude (A1-A6), and Group 3 tested the level of practice of PV (P1-P5) of the participant. Such 250 questionnaires were distributed to different health-care professionals of VIMS, Ballari. The participants were graded in three categories as poor, unsatisfactory, and satisfactory depending on the mean score. The data were interpreted by calculating the frequencies, one-way ANOVA and Scheffe's test. Furthermore, factors that discourage them from taking part in the PV program were recorded. A total of 182 questionnaires were statistically analyzed. It was found that KAP of PV among doctors, nurses, and pharmacists was unsatisfactory. Our study showed that knowledge, attitude, and level of practice of PV among doctors, nurses, and pharmacists stand inadequate. Educational interventions periodically can improve these parameters of PV.Entities:
Keywords: Adverse drug reaction; attitude; knowledge; pharmacovigilance; practice
Year: 2019 PMID: 31041185 PMCID: PMC6474162 DOI: 10.4103/japtr.JAPTR_4_19
Source DB: PubMed Journal: J Adv Pharm Technol Res ISSN: 0976-2094
Mean knowledge, attitude, and practice scores among different health-care professionals
| Parameters | Profession | Mean | SD | |||
|---|---|---|---|---|---|---|
| Knowledge | Nurse | 64 | 2.88 | 1.23 | 3.88 | 0.02* |
| Pharmacist | 11 | 2.82 | 0.98 | |||
| Doctors | 107 | 3.39 | 1.29 | |||
| Total | 182 | 3.18 | 1.28 | |||
| Attitude | Nurse | 64 | 2.88 | 1.21 | 0.2 | 0.819 |
| Pharmacist | 11 | 3.00 | 1.55 | |||
| Doctors | 107 | 2.80 | 1.00 | |||
| Total | 182 | 2.84 | 1.11 | |||
| Practice | Nurse | 64 | 2.73 | 0.60 | 3.78 | 0.024* |
| Pharmacist | 11 | 2.91 | 1.04 | |||
| Doctors | 107 | 2.47 | 0.77 | |||
| Total | 182 | 2.59 | 0.74 |
*The statistical significance. SD: Standard deviation
Practice related responses of pharmacovigilance from study participants
| Question | Correct response | Health professional | ||
|---|---|---|---|---|
| Nurse, | Pharmacist, | Doctors, | ||
| Which of the method is commonly implied by pharmaceutical companies for PV of new drugs once they are launched in the market? | Postmarketing surveillance studies | 62 (96.9) | 10 (90.9) | 102 (95.3) |
| ADR reporting can be done by | All are correct (Doctors, Nurses, and Pharmacists) | 3 (4.7) | 0 (0.0) | 0 (0.0) |
| Augmented drug reaction is | Dose dependent, common in occurrence, rarely fatal | 60 (93.8) | 6 (54.5) | 58 (54.2) |
| Which of the following scales is most commonly used to establish the causality of an ADR? | Naranjo algorithm | 52 (81.3) | 8 (72.7) | 30 (28.0) |
| Elements which are mandatory to record | All (identifiable patient, reporter and suspected medicinal products) | 54 (84.4) | 9 (81.8) | 88 (82.2) |
PV: Pharmacovigilance, ADR: Adverse drug reaction
Figure 1Scoring scale of knowledge, attitude and practice among study participants
ANOVA test of significance for comparison among the groups of each health-care professionals
| Sum of squares | Df | Mean square | Significance | ||
|---|---|---|---|---|---|
| Mean_K_Score | |||||
| Between groups | 12.223 | 2 | 6.112 | 3.877 | 0.022* |
| Within groups | 282.150 | 179 | 1.576 | ||
| Total | 294.374 | 181 | |||
| Mean_A_Score | |||||
| Between groups | 0.501 | 2 | 0.250 | 0.200 | 0.819 |
| Within groups | 223.879 | 179 | 1.251 | ||
| Total | 224.379 | 181 | |||
| Mean_P_Score | |||||
| Between groups | 4.064 | 2 | 2.032 | 3.788 | 0.024* |
| Within groups | 96.029 | 179 | 0.536 | ||
| Total | 100.093 | 181 |
*The statistical significance
Post hoc Scheffe’s test for multiple comparisons
| Dependent variable | Mean difference (I-J) | SE | Significance | 95% CI | |
|---|---|---|---|---|---|
| Lower bound | Upper bound | ||||
| Mean_K_Score | |||||
| Nurse | |||||
| Pharmacist | 0.05682 | 0.40979 | 0.990 | −0.9547 | 1.0683 |
| Doctors | −0.51752* | 0.19839 | 0.035* | −1.0072 | −0.0278 |
| Pharmacist | |||||
| Nurse | −0.05682 | 0.40979 | 0.990 | −1.0683 | 0.9547 |
| Doctors | −0.57434 | 0.39753 | 0.354 | −1.5556 | 0.4069 |
| Doctors | |||||
| Nurse | 0.51752* | 0.19839 | 0.035* | 0.0278 | 1.0072 |
| Pharmacist | 0.57434 | 0.39753 | 0.354 | −0.4069 | 1.5556 |
| Mean_A_Score | |||||
| Nurse | |||||
| Pharmacist | −0.12500 | 0.36503 | 0.943 | −1.0260 | 0.7760 |
| Doctors | 0.07126 | 0.17672 | 0.922 | −0.3650 | 0.5075 |
| Pharmacist | |||||
| Nurse | 0.12500 | 0.36503 | 0.943 | −0.7760 | 1.0260 |
| Doctors | 0.19626 | 0.35411 | 0.858 | −0.6778 | 1.0703 |
| Doctors | |||||
| Nurse | −0.07126 | 0.17672 | 0.922 | −0.5075 | 0.3650 |
| Pharmacist | −0.19626 | 0.35411 | 0.858 | −1.0703 | 0.6778 |
| Mean_P_Score | |||||
| Nurse | |||||
| Pharmacist | −0.17472 | 0.23907 | 0.766 | −0.7648 | 0.4154 |
| Doctors | 0.26709 | 0.11574 | 0.073 | −0.0186 | 0.5528 |
| Pharmacist | |||||
| Nurse | 0.17472 | 0.23907 | 0.766 | −0.4154 | 0.7648 |
| Doctors | 0.44180 | 0.23191 | 0.166 | −0.1306 | 1.0143 |
| Doctors | |||||
| Nurse | −0.26709 | 0.11574 | 0.073 | −0.5528 | 0.0186 |
| Pharmacist | −0.44180 | 0.23191 | 0.166 | −1.0143 | 0.1306 |
*The statistical significance. SE: Standard error, CI: Confidence interval
Factors discouraging to take part in pharmacovigilance program
| Factors discouraging to take part in PV program | Nurse | Pharmacist | Doctors |
|---|---|---|---|
| Not knowing how and where to report | 12.5 | 72.7 | 59.8 |
| Patient confidentiality issues | 9.4 | 9.1 | 8.4 |
| A single unreported case a not affect ADR database | 54.7 | 0 | 9.3 |
| Difficult to decide whether ADR had occurred or not | 23.4 | 18.2 | 22.4 |
ADR: Adverse drug reaction, PV: Pharmacovigilance
Knowledge related responses of pharmacovigilance from study participants
| Question | Correct response | Health professional | ||
|---|---|---|---|---|
| Nurse (64), | Pharmacist (11), | Doctors (107), | ||
| Are you aware of term PV | Yes | 62 (96.90) | 10 (90.90) | 91 (85.00) |
| PV is defined as | Detection, assessment, understanding, and prevention of adverse drug effects | 17 (26.60) | 2 (18.20) | 39 (36.40) |
| The aim of PV is to assess | Safety over efficacy | 41 (64.10) | 8 (72.70) | 92 (86.00) |
| PV include | All are correct (drug, blood, herbal, vaccines, and medical devices related | 24 (37.50) | 2 (18.20) | 36 (33.60) |
| The PV Program of India was officially launched in the year | 2010 | 9 (14.10) | 2 (18.20) | 42 (39.30) |
| The international center for ADR monitoring is located in | Sweden | 12 (18.80) | 5 (45.50) | 41 (38.30) |
| Which of the following is the “WHO online databases” for reporting ADR’s? | Vigibase | 16 (25.00) | 2 (18.20) | 21 (19.60) |
| There are how many ADR monitoring Centres in India? | 179 | 3 (4.70) | 0 (0.00) | 1 (0.90) |
WHO: World Health Organisation, ADR’s: Adverse drug reactions, PV: Pharmacovigilance
Attitude related responses of pharmacovigilance from study participants
| Questions | Correct answer | Nurse, | Pharmacist, | Doctors, |
|---|---|---|---|---|
| What is your opinion about establishing ADR monitoring centre in every hospital? | Should be in every hospital | 19 (29.70) | 4 (36.40) | 44 (41.10) |
| Do you think reporting of ADRs is necessary? | Yes | 29 (45.30) | 8 (72.70) | 44 (41.10) |
| Do you think PV should be taught in detail to health-care professionals? | Yes | 37 (57.80) | 7 (63.60) | 93 (86.90) |
| Have you ever been come across educational session in specific about PV? | Yes | 57 (89.10) | 7 (63.60) | 69 (64.50) |
| Have you any time read any article on prevention of ADR’s? | Yes | 37 (57.80) | 2 (18.20) | 41 (38.30) |
| Nonmedical person can report ADR to a nearby healthcare professional? | Yes | 3 (4.70) | 0 (0.00) | 7 (6.50) |
ADR’s: Adverse drug reactions, PV: Pharmacovigilance